Generic placeholder image

当代阿耳茨海默病研究

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Research Article

改进的K114方法对啮齿动物斑块和人脑组织斑块和缠结的定位评价和表征

卷 21, 期 1, 2024

发表于: 01 April, 2024

页: [69 - 80] 页: 12

弟呕挨: 10.2174/0115672050295561240327055835

价格: $65

摘要

背景:大量的研究表明,由于几种化学染料与Aβ的亲和力,它们可以在光镜或荧光显微镜下显示斑块,其中一些化学染料也显示出与神经原纤维缠结(NFT)的亲和力。然而,只有少数具有同时结合老年斑(SP)和NFT的倾向。 目的:在我们目前的研究中,我们旨在修改K114染料和染色程序,以大幅度改善人类和啮齿动物大脑中淀粉样斑块和人类大脑中神经原纤维缠结的染色。 方法:以苏丹黑为改性剂对K114溶液及染色工艺进行改性。此外,为了评估修饰后的K114的靶标,我们对K114进行了双标记,并针对三个不同的表位增加了Aβ。我们使用了5种不同的抗体来检测磷酸化的tau蛋白,以了解修饰的K114结合的特定靶标。 结果:使用抗AT8、pTau和TNT1的过度磷酸化抗体进行双重标记显示,超过80%的过度磷酸化tau蛋白与修饰K114阳性的缠结共定位,而超过70%的过度磷酸化tau蛋白与修饰K114共定位。另一方面,用Aβ MOAB-2染色的斑块中超过80%与修饰的K114共定位。 结论:改进的方法可在大鼠脑内5 min内标记淀粉样斑块,在人脑中20 min内标记淀粉样斑块。我们的研究结果表明,修饰的K114可以作为检测淀粉样蛋白斑块和缠结的有价值的工具,相对于其他传统的荧光标记物具有高对比度和分辨率。

关键词: 淀粉样蛋白,斑块,神经原纤维缠结,组织化学示踪剂,苯乙烯,阿尔茨海默病,磷酸化tau。

[1]
2023 Alzheimer’s disease facts and figures. Alzheimers Dement., 2023, 19(4), 1598-1695.
[http://dx.doi.org/10.1002/alz.13016] [PMID: 36918389]
[2]
Hardy, J.; Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol. Sci., 1991, 12(10), 383-388.
[http://dx.doi.org/10.1016/0165-6147(91)90609-V] [PMID: 1763432]
[3]
Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science, 2002, 297(5580), 353-356.
[http://dx.doi.org/10.1126/science.1072994] [PMID: 12130773]
[4]
Hardy, J.A.; Higgins, G.A. Alzheimer’s disease: The amyloid cascade hypothesis. Science, 1992, 256(5054), 184-185.
[http://dx.doi.org/10.1126/science.1566067] [PMID: 1566067]
[5]
Alonso, A.C.; Grundke-Iqbal, I.; Barra, H.S.; Iqbal, K. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: Sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc. Natl. Acad. Sci. USA, 1997, 94(1), 298-303.
[http://dx.doi.org/10.1073/pnas.94.1.298] [PMID: 8990203]
[6]
Alonso, A.C.; Grundke-Iqbal, I.; Iqbal, K. Alzheimer’s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat. Med., 1996, 2(7), 783-787.
[http://dx.doi.org/10.1038/nm0796-783] [PMID: 8673924]
[7]
Alonso, A.; Li, B.; Grundke-Iqbal, I.; Iqbal, K. Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies. Curr. Alzheimer Res., 2008, 5(4), 375-384.
[http://dx.doi.org/10.2174/156720508785132307] [PMID: 18690834]
[8]
Iqbal, K.; Alonso, A.C.; Grundke-Iqbal, I. Cytosolic abnormally hyperphosphorylated tau but not paired helical filaments sequester normal MAPs and inhibit microtubule assembly. J. Alzheimers Dis., 2008, 14(4), 365-370.
[http://dx.doi.org/10.3233/JAD-2008-14402] [PMID: 18688085]
[9]
Aghourian, M.; Aumont, É.; Grothe, M.J.; Soucy, J.P.; Rosa-Neto, P.; Bedard, M.A. FEOBV-PET to quantify cortical cholinergic denervation in AD: Relationship to basal forebrain volumetry. J. Neuroimaging, 2021, 31(6), 1077-1081.
[http://dx.doi.org/10.1111/jon.12921] [PMID: 34462992]
[10]
Aghourian, M.; Legault-Denis, C.; Soucy, J-P.; Rosa-Neto, P.; Gauthier, S.; Kostikov, A.; Gravel, P.; Bédard, M-A. Quantification of brain cholinergic denervation in Alzheimer’s disease using PET imaging with [18F]-FEOBV. Mol. Psychiatry, 2017, 22(11), 1531-1538.
[http://dx.doi.org/10.1038/mp.2017.183] [PMID: 28894304]
[11]
Bedard, M.A.; Aghourian, M.; Legault-Denis, C.; Postuma, R.B.; Soucy, J.P.; Gagnon, J.F.; Pelletier, A.; Montplaisir, J. Brain cholinergic alterations in idiopathic REM sleep behaviour disorder: A PET imaging study with 18F-FEOBV. Sleep Med., 2019, 58, 35-41.
[http://dx.doi.org/10.1016/j.sleep.2018.12.020] [PMID: 31078078]
[12]
Nejad-Davarani, S.; Koeppe, R.A.; Albin, R.L.; Frey, K.A.; Müller, M.L.T.M.; Bohnen, N.I. Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with [18F]-FEOBV. Mol. Psychiatry, 2019, 24(3), 322-327.
[http://dx.doi.org/10.1038/s41380-018-0130-5] [PMID: 30082840]
[13]
de la Torre, J.; Aliev, G.; Perry, G. Drug therapy in Alzheimer’s disease. N. Engl. J. Med., 2004, 351(18), 1911-1913.
[http://dx.doi.org/10.1056/NEJM200410283511822] [PMID: 15509830]
[14]
de La Torre, J.C. Alzheimer’s disease is a vasocognopathy: A new term to describe its nature. Neurol. Res., 2004, 26(5), 517-524.
[http://dx.doi.org/10.1179/016164104225016254] [PMID: 15265269]
[15]
de la Torre, J.C. Is Alzheimer’s disease a neurodegenrative or vascular disorder? (vol 3, pg 184, 2004). Lancet Neurol., 2004, 3(5), 270-270.
[PMID: 15099540]
[16]
Scheffer, S.; Hermkens, D.M.A.; van der Weerd, L.; de Vries, H.E.; Daemen, M.J.A.P. Vascular hypothesis of Alzheimer disease. Arterioscler. Thromb. Vasc. Biol., 2021, 41(4), 1265-1283.
[http://dx.doi.org/10.1161/ATVBAHA.120.311911] [PMID: 33626911]
[17]
Bourgade, K. Anti-viral properties of Amyloid-β Peptides., J Alzheimers Dis., 2016, 54(3), 859-878.
[18]
Bourgade, K.; Garneau, H.; Giroux, G.; Le Page, A.Y.; Bocti, C.; Dupuis, G.; Frost, E.H.; Fülöp, T., Jr β-Amyloid peptides display protective activity against the human Alzheimer’s disease-associated herpes simplex virus-1. Biogerontology, 2015, 16(1), 85-98.
[http://dx.doi.org/10.1007/s10522-014-9538-8] [PMID: 25376108]
[19]
Bourgade, K.; Le Page, A.; Bocti, C.; Witkowski, J.M.; Dupuis, G.; Frost, E.H.; Fülöp, T., Jr Protective effect of Amyloid-β Peptides against Herpes Simplex Virus-1 infection in a neuronal cell culture model. J. Alzheimers Dis., 2016, 50(4), 1227-1241.
[http://dx.doi.org/10.3233/JAD-150652] [PMID: 26836158]
[20]
Fulop, T.; Ramassamy, C.; Lévesque, S.; Frost, E.H.; Laurent, B.; Lacombe, G.; Khalil, A.; Larbi, A.; Hirokawa, K.; Desroches, M.; Rodrigues, S.; Bourgade, K.; Cohen, A.A.; Witkowski, J.M. Viruses - a major cause of amyloid deposition in the brain. Expert Rev. Neurother., 2023, 23(9), 775-790.
[http://dx.doi.org/10.1080/14737175.2023.2244162] [PMID: 37551672]
[21]
Fulop, T.; Witkowski, J.M.; Bourgade, K.; Khalil, A.; Zerif, E.; Larbi, A.; Hirokawa, K.; Pawelec, G.; Bocti, C.; Lacombe, G.; Dupuis, G.; Frost, E.H. Can an infection hypothesis explain the beta amyloid hypothesis of Alzheimer’s disease? Front. Aging Neurosci., 2018, 10, 224.
[http://dx.doi.org/10.3389/fnagi.2018.00224] [PMID: 30087609]
[22]
Akiyama, H.; Arai, T.; Kondo, H.; Tanno, E.; Haga, C.; Ikeda, K. Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis. Assoc. Disord., 2000, 14(Suppl.), S47-S53.
[http://dx.doi.org/10.1097/00002093-200000001-00008] [PMID: 10850730]
[23]
Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G.M.; Cooper, N.R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B.L.; Finch, C.E.; Frautschy, S.; Griffin, W.S.; Hampel, H.; Hull, M.; Landreth, G.; Lue, L.; Mrak, R.; Mackenzie, I.R.; McGeer, P.L.; O’Banion, M.K.; Pachter, J.; Pasinetti, G.; Plata-Salaman, C.; Rogers, J.; Rydel, R.; Shen, Y.; Streit, W.; Strohmeyer, R.; Tooyoma, I.; Van Muiswinkel, F.L.; Veerhuis, R.; Walker, D.; Webster, S.; Wegrzyniak, B.; Wenk, G.; Wyss-Coray, T. Inflammation and Alzheimer’s disease. Neurobiol. Aging, 2000, 21(3), 383-421.
[http://dx.doi.org/10.1016/S0197-4580(00)00124-X] [PMID: 10858586]
[24]
Pillai, J.A.; Bena, J.; Bebek, G.; Bekris, L.M.; Bonner-Jackson, A.; Kou, L.; Pai, A.; Sørensen, L.; Neilsen, M.; Rao, S.M.; Chance, M.; Lamb, B.T.; Leverenz, J.B. Inflammatory pathway analytes predicting rapid cognitive decline in MCI stage of Alzheimer’s disease. Ann. Clin. Transl. Neurol., 2020, 7(7), 1225-1239.
[http://dx.doi.org/10.1002/acn3.51109] [PMID: 32634865]
[25]
Pillai, J.A.; Maxwell, S.; Bena, J.; Bekris, L.M.; Rao, S.M.; Chance, M.; Lamb, B.T.; Leverenz, J.B. Key inflammatory pathway activations in the MCI stage of Alzheimer’s disease. Ann. Clin. Transl. Neurol., 2019, 6(7), 1248-1262.
[http://dx.doi.org/10.1002/acn3.50827] [PMID: 31353852]
[26]
Cummings, J.; Aisen, P.; Lemere, C.; Atri, A.; Sabbagh, M.; Salloway, S. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimers Res. Ther., 2021, 13(1), 98.
[http://dx.doi.org/10.1186/s13195-021-00838-z] [PMID: 33971962]
[27]
Padala, S.P.; Yarns, B.C. Under-represented populations left out of alzheimer’s disease treatment with aducanumab: Commentary on ethics. J. Alzheimers Dis. Rep., 2022, 6(1), 345-348.
[http://dx.doi.org/10.3233/ADR-220023] [PMID: 35891635]
[28]
Stepanchuk, A.A.; Heyne, B.; Stys, P.K. Complex photophysical properties of k114 make for a versatile fluorescent probe for amyloid detection. ACS Chem. Neurosci., 2021, 12(7), 1273-1280.
[http://dx.doi.org/10.1021/acschemneuro.1c00101] [PMID: 33705095]
[29]
Setti, S.E.; Raymick, J.; Hanig, J.; Sarkar, S. In vivo demonstration of Congo Red labeled amyloid plaques via perfusion in the Alzheimer disease rat model. J. Neurosci. Methods, 2021, 353, 109082.
[http://dx.doi.org/10.1016/j.jneumeth.2021.109082] [PMID: 33508413]
[30]
Iadanza, M.G.; Jackson, M.P.; Hewitt, E.W.; Ranson, N.A.; Radford, S.E. A new era for understanding amyloid structures and disease. Nat. Rev. Mol. Cell Biol., 2018, 19(12), 755-773.
[http://dx.doi.org/10.1038/s41580-018-0060-8] [PMID: 30237470]
[31]
Selmani, V.; Robbins, K.J.; Ivancic, V.A.; Lazo, N.D. K114 ( trans, trans )-bromo-2,5-bis(4-hydroxystyryl)benzene is an efficient detector of cationic amyloid fibrils. Protein Sci., 2015, 24(3), 420-425.
[http://dx.doi.org/10.1002/pro.2620] [PMID: 25524064]
[32]
LeVine, H., III Mechanism of Aβ(1−40) Fibril-Induced Fluorescence of ( trans, trans )-1-Bromo-2,5-bis(4-hydroxystyryl)benzene (K114). Biochemistry, 2005, 44(48), 15937-15943.
[http://dx.doi.org/10.1021/bi051252l] [PMID: 16313197]
[33]
Crystal, A.S.; Giasson, B.I.; Crowe, A.; Kung, M.P.; Zhuang, Z.P.; Trojanowski, J.Q.; Lee, V.M.Y. A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114. J. Neurochem., 2003, 86(6), 1359-1368.
[http://dx.doi.org/10.1046/j.1471-4159.2003.01949.x] [PMID: 12950445]
[34]
Stepanchuk, A.A.; Barber, P.A.; Lashley, T.; Joseph, J.T.; Stys, P.K. Quantitative detection of grey and white matter amyloid pathology using a combination of K114 and CRANAD-3 fluorescence. Neurobiol. Dis., 2021, 161, 105540.
[http://dx.doi.org/10.1016/j.nbd.2021.105540] [PMID: 34751140]
[35]
Elghetany, M.T.; Saleem, A. Methods for staining amyloid in tissues: A review. Stain Technol., 1988, 63(4), 201-212.
[http://dx.doi.org/10.3109/10520298809107185] [PMID: 2464206]
[36]
Glenner, G.G.; Eanes, E.D.; Page, D.L. The relation of the properties of Congo red-stained amyloid fibrils to the -conformation. J. Histochem. Cytochem., 1972, 20(10), 821-826.
[http://dx.doi.org/10.1177/20.10.821] [PMID: 4638557]
[37]
Styren, S.D.; Hamilton, R.L.; Styren, G.C.; Klunk, W.E. X-34, a fluorescent derivative of Congo red: A novel histochemical stain for Alzheimer’s disease pathology. J. Histochem. Cytochem., 2000, 48(9), 1223-1232.
[http://dx.doi.org/10.1177/002215540004800906] [PMID: 10950879]
[38]
Skovronsky, D.M.; Zhang, B.; Kung, M.P.; Kung, H.F.; Trojanowski, J.Q.; Lee, V.M.Y. In vivo detection of amyloid plaques in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA, 2000, 97(13), 7609-7614.
[http://dx.doi.org/10.1073/pnas.97.13.7609] [PMID: 10861023]
[39]
Schmidt, M.L.; Schuck, T.; Sheridan, S.; Kung, M.P.; Kung, H.; Zhuang, Z.P.; Bergeron, C.; Lamarche, J.S.; Skovronsky, D.; Giasson, B.I.; Lee, V.M.Y.; Trojanowski, J.Q. The fluorescent Congo red derivative, (trans, trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB), labels diverse β-pleated sheet structures in postmortem human neurodegenerative disease brains. Am. J. Pathol., 2001, 159(3), 937-943.
[http://dx.doi.org/10.1016/S0002-9440(10)61769-5] [PMID: 11549586]
[40]
Setti, S.E.; Das, N.; Raymick, J.; Hanig, J.; Sarkar, S. Evaluation of Styrylbenzene analog- FSB and its affinity to bind parenchymal plaques and tangles in patients of Alzheimer’s disease. Metab. Brain Dis., 2022, 37(3), 639-651.
[http://dx.doi.org/10.1007/s11011-021-00885-3] [PMID: 35064472]
[41]
Puchtler, H.; Sweat, F. Congo red as a stain for fluorescence microscopy of amyloid. J. Histochem. Cytochem., 1965, 13(8), 693-694.
[http://dx.doi.org/10.1177/13.8.693] [PMID: 4160077]
[42]
Kelényi, G. Thioflavin S fluorescent and Congo red anisotropic stainings in the histologic demonstration of amyloid. Acta Neuropathol., 1967, 7(4), 336-348.
[http://dx.doi.org/10.1007/BF00688089] [PMID: 4166287]
[43]
Schmued, L.; Raymick, J.; Tolleson, W.; Sarkar, S.; Zhang, Y.H.; Bell-Cohn, A. Introducing Amylo-Glo, a novel fluorescent amyloid specific histochemical tracer especially suited for multiple labeling and large scale quantification studies. J. Neurosci. Methods, 2012, 209(1), 120-126.
[http://dx.doi.org/10.1016/j.jneumeth.2012.05.019] [PMID: 22705750]
[44]
Åslund, A.; Sigurdson, C.J.; Klingstedt, T.; Grathwohl, S.; Bolmont, T.; Dickstein, D.L.; Glimsdal, E.; Prokop, S.; Lindgren, M.; Konradsson, P.; Holtzman, D.M.; Hof, P.R.; Heppner, F.L.; Gandy, S.; Jucker, M.; Aguzzi, A.; Hammarström, P.; Nilsson, K.P.R. Novel pentameric thiophene derivatives for in vitro and in vivo optical imaging of a plethora of protein aggregates in cerebral amyloidoses. ACS Chem. Biol., 2009, 4(8), 673-684.
[http://dx.doi.org/10.1021/cb900112v] [PMID: 19624097]
[45]
Sigurdson, C.J.; Nilsson, K.P.R.; Hornemann, S.; Manco, G.; Polymenidou, M.; Schwarz, P.; Leclerc, M.; Hammarström, P.; Wüthrich, K.; Aguzzi, A. Prion strain discrimination using luminescent conjugated polymers. Nat. Methods, 2007, 4(12), 1023-1030.
[http://dx.doi.org/10.1038/nmeth1131] [PMID: 18026110]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy